News

Inaugural Maddie Riewoldt's Vision National Symposium on Bone Marrow Failure Syndromes

The Aplastic Anaemia Registry team is pleased to support the inaugural Maddie Riewoldt's Vision National Symposium on Bone Marrow Failure Syndromes in Melbourne, 25-26 May 2019.

Find preliminary information on the Symposium at: mrv.org.au/news/86/inaugural-maddie-riewoldts-vision-national-symposium-on-bone-marrow-failure-syndromes

2,500th patient recruited to the MRDR

Among its registry projects, TRU manages the Myeloma and Related Diseases Registry (MRDR). The MRDR, chaired by Professor Andrew Spencer of the Alfred Hospital, captures and analyses data on patterns of treatment and variation in patient outcomes (both survival and quality of life) for patients with multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS). The first patients were enrolled in 2013. More than 30 sites from Australia and New Zealand are already participating and additional sites are continuing to join.

Congratulations to Christchurch Hospital in New Zealand who recruited the 2,500th patient!

Ultimately, MRDR data will help clinicians and hospitals to provide the best possible care to people with myeloma and MGUS and allow evaluation of the translation of advances in therapy (such as the introduction of new targeted therapies) into long-term outcomes, outside the setting of clinical trials.

More information on the MRDR and its projects is available at: mrdr.net.au
Information on the Asia-Pacific expansion of the MRDR is available at: apacmrdr.org

400th patient recruited to the TREATT trial

TREATT is a randomised trial of tranexamic acid (TXA, an anti-fibrinolytic agent to prevent clot breakdown) or placebo to investigate whether TXA prevents bleeding in adult patients with a haematologic malignancy and profound thrombocytopenia.

TREATT is a collaboration between the NHS Blood and Transplant in the UK and Monash University. The Australian arm of the trial is funded by the NHMRC and the Australian and New Zealand Society of Blood Transfusion. Ten Australian hospitals are currently participating.

More information is available at treatt.org

Congratulations to the team at Peter MacCallum Cancer Centre in Melbourne who recruited the 400th patient!

TRU at the American Society of Hematology conference

Prof Erica Wood, A/Prof Zoe McQuilten and Dr Lucy Fox represented TRU at the recent ASH meeting in San Diego.

Data from the UK-Canada-Australian REDDS pilot study of red cell transfusion in patients with myelodysplasia were presented as an oral abstract by Dr David Bowen, with Zoe McQuilten as a co-author. See abstract 527: A Feasibility Randomized Trial of Red Cell Transfusion Thresholds in Myelodysplasia. Available at: https://ash.confex.com/ash/2018/webprogram/Paper112949.html

Lucy Fox and Erica Wood were co-authors on a poster presenting data from the Melbourne Genomics Health Alliance Bone Marrow Failure Flagship. See abstract 3867: Providing Diagnoses in Bone Marrow Failure Syndromes through Multimodal Comprehensive Genomic Evaluation and Multidisciplinary Care: The Melbourne Genomics Health Alliance Bone Marrow Failure Flagship. Available at https://ash.confex.com/ash/2018/webprogram/Paper114410.html

Zoe and Erica also met with colleagues for a steering committee meeting of the Asia-Pacific Myeloma and Related Diseases Registry, and made a presentation to the Myeloma Canada Research Network.

ICAN study – Immunoglobulin use in Chronic lymphocytic leukaemia And Non-Hodgkin lymphoma – funded by the National Blood Authority

Patients with certain types of non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukaemia (CLL), are at increased risk of infections due to the effects of their disease and treatment on levels of protective antibodies. Immunoglobulin therapy (made from donated plasma) is commonly used to prevent infections by replacing protective antibodies in this patient group, and is one of the most common and fastest growing indications in Australia. Availability of novel treatments with profound and protracted immunosuppressive effects will likely mean that immunoglobulin demand will continue to grow.

However, there is limited evidence from clinical studies to guide clinicians on which patients are most likely to benefit, when to commence treatment, or for how long. The role of other strategies to prevent infection, such as prophylactic antibiotics and immunisations, have not been well studied.

Working with the Australian Lymphoma and Related Disease Registry and the newly established CLL Registry, both managed by TRU, the ICAN project will collect data on current immunoglobulin replacement and other infection prevention strategies, as well as patient-centred outcomes, in Australian patients with CLL and NHL. In a subgroup of participants, the study will also collect serial blood samples for novel immune-profiling studies.

The ICAN investigators are Zoe McQuilten, Erica Wood and Neil Waters from Monash University’s Transfusion Research Unit; other Monash University colleagues Orla Morrissey, Stephen Opat, Jonathan Wong and John Zalcberg; Philip Crispin from Canberra Hospital; Stephen Mulligan and Kyle Crassini from Royal North Shore Hospital/University of Sydney; and Monica Slavin and Benjamin Teh from Peter MacCallum Cancer Centre/ NHRMC National Centre for Infections in Cancer.

NHMRC success with the ASPREE-CHIP study for TRU’s A/Prof Zoe McQuilten and colleagues

A/Prof Zoe McQuilten and colleagues have been awarded $1,416 million for a study of clonal haematopoiesis of indeterminate potential (CHIP) in the elderly. This project will investigate CHIP in participants from the ASPirin in Reducing Events in the Elderly (ASPREE) study, a randomised controlled trial of daily low-dose aspirin or placebo in over 19,000 elderly but otherwise well individuals (www.aspree.org).

CHIP is the presence of a haematological malignancy-associated somatic mutation in blood or marrow without evidence of haematological disease. CHIP is increasingly common with increasing age, and is associated with risk of haematological cancers, coronary heart disease and ischemic stroke. Mouse models support a causative link between CHIP and development of atherosclerosis. However, very few studies have been performed in humans to date, and fundamental gaps remain in our understanding.

Using ASPREE trial data on incident haematological cancers, cardiovascular events, stroke, dementia and all-cause mortality, and biobanked samples at baseline and 3 years, we will study CHIP and its clinical consequences. We will also investigate the role of inflammation, and whether reducing inflammation through use of low-dose aspirin alters incidence, progression and consequences of CHIP.

Investigators on the NHMRC-funded grant are: Zoe McQuilten and Erica Wood from Monash University’s Transfusion Research Unit, other Monash University colleagues David Curtis, Rory Wolfe, Paul Lacaze, John McNeil, Andrew Murphy, Moeen Riaz, Nick Wong and Robyn Woods, and Robert Sebra Icahn School of Medicine at Mount Sinai, USA.

CLIP-II study of frozen platelets funded by NHMRC

CLIP-II is a phase III, multicentre blinded randomised controlled clinical non-inferiority trial of cryopreserved platelets versus conventional liquid-stored platelets for the management of post-cardiac surgical bleeding.

The CLIP-II team have been awarded $1.825 million by the NHMRC for the project.

CLIP Chief Investigator Dr Michael Reade leads a team of experts from around Australia and New Zealand, including Drs Zoe McQuilten and Erica Wood of the Transfusion Research Unit at Monash University.

Sharing Massive Transfusion Registry data with transfusion practitioners

Dr Rosemary Sparrow and Mrs Helen Haysom provided an update on the Massive Transfusion Registry as part of the Blood Matters Transfusion Forum in November.

The MTR now has data on over 8000 cases of critical bleeding from 29 hospitals across all clinical contexts, including trauma, obstetrics, surgery and gastrointestinal haemorrhage. An additional 20 sites are in the process of joining. The MTR is proving valuable for both research and for clinical practice improvement and benchmarking, and data are provided to participating sites via hospital data reports, letters and presentations. Results have been presented this year at the BLOOD 2018 conference in Brisbane, the International Society of Blood Transfusion congress in Toronto, and the AABB conference in Boston, as well as through several publications.

Current MTR research projects include analyses of:

  • use of group O, RhD negative red cells in critical bleeding
  • ratios of FFP to red cells transfused in early traumatic resuscitation
  • management and outcomes of major obstetric haemorrhage
  • impact of age of transfused red cells in massive transfusion events
  • ultramassive transfusions
  • rapid infusion practices
  • age of platelets in massive transfusion events
  • major bleeding in patients undergoing cardiac surgery in partnership with the Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) database

If you have an idea for a project using MTR data, please get in touch with us: sphpm.mtr@monash.edu

TRU at BLOOD 2018 conference

The Transfusion Research Unit was well represented at the recent Australian and New Zealand annual haematology and transfusion conference, BLOOD 2018, held in Brisbane. Staff and collaborators contributed two invited presentations, nine oral abstracts and seven posters. Congratulations to Dr Elizabeth Moore who received a poster prize.

TRU’s exhibition booth was a great opportunity to profile the Unit’s research and hold informal discussions with delegates. Breakfast meetings for the lymphoma and myeloma registries included presentations by invited speakers as well as review of registry data and project updates, and were well attended by clinicians and industry partners.

Dr Rosemary Sparrow awarded honorary membership of BEST Collaborative

Dr Rosemary Sparrow represented the Transfusion Research Unit team at the Biomedical Excellence for Safer Transfusion (BEST) Collaborative meeting that was held in Newport, Rhode Island (USA). BEST is an international research group, with scientific membership drawn from individuals recognised as having high-level accomplishments in transfusion research. TRU is an institutional member of BEST.

Congratulations to Rosemary for being made an honorary member for her previous and ongoing contributions to BEST and transfusion research, and becoming the first Australian to be awarded this honour.

TRU at AABB 2018 meeting

The Transfusion Research Unit was well represented at the AABB (formerly American Association of Blood Banks) annual meeting in Boston, USA. TRU team members contributed two posters and one oral abstract. Congratulations to PhD student Phil Kiely who received a top poster award for 'Modelling the transfusion-transmission risk of West Nile Virus in Australia associated with travelling blood donors'. Dr Rosemary Sparrow (left) presented a poster on the use of group O negative red cells in critical bleeding, on behalf of the Massive Transfusion Registry investigators.

Prof Erica Wood and Dr Zoe McQuilten co-authored an abstract on an Australian clinical trial of cryopreserved platelets in cardiac surgery, presented in the Plenary Oral Abstract Session for the top six submitted abstracts.

ASPREE trial published in New England Journal of Medicine

The results of the Australia-US ASPREE trial of low-dose aspirin in the elderly have been published in three concurrent papers in the New England Journal of Medicine.

One of the publications focussed on clinically significant bleeding. Prof Erica Wood of Monash University’s Transfusion Research Unit chaired the ASPREE clinically significant bleeding panel and was one of the authors on this paper.

See: McNeil JJ, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi: 10.1056/NEJMoa1805819.

More information is available at: aspree.org/aus

Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma – the FRAIL-M study – funded by the Medical Research Future Fund

TRU’s Zoe McQuilten, Erica Wood, Elizabeth Moore and Cameron Wellard are investigators on the FRAIL-M study. The project will utilise the infrastructure of the Myeloma and Related Diseases Registry (MRDR) managed by Monash University’s Transfusion Research Unit. Professor Andrew Spencer (Monash University/Alfred Hospital) is Chief Investigator A on FRAIL-M and chair of the MRDR Steering Committee. Funding of $1.642 million has been awarded by the MRFF through its call for applications for “Low Survival Cancers and Diseases”.

Current Australian guidelines recommend that up-front therapy for transplant-ineligible myeloma patients should be either bortezomib- or lenlidomide-based regimens, with dosing adjusted according to patient frailty. However, adapting treatment dose according to frailty assessment has not been tested in a clinical trial.

FRAIL-M is a stratified randomised controlled trial to identify which competing treatment options are more appropriate in transplant-ineligible myeloma patients according to frailty status. Participants will be stratified into three groups (fit, intermediate-fit or frail) based on a standardised and validated frailty assessment, and randomised to a bortezomib- vs a lenalidomide-based regimen, with dosing adjusted according to frailty stratum. A Bayesian Optimal Phase II design will allow us to jointly monitor efficacy and toxicity, with further adjustments if individual treatment arms appear either too toxic or ineffective.

The FRAIL-M investigators are Andrew Spencer, Zoe McQuilten, Hang Quach, Peter Mollee, Erica Wood, John Reynolds, Ruth Hubbard, Richard De Abreu Lourenco, Cameron Wellard, Elizabeth Moore, Madeleine King, Steve Roach and Tracy King.

TRU congratulates Dr Nicholas Saadah who was awarded his PhD from the University of Leiden on 11 September 2018

Nic’s thesis was entitled: Hemovigilance, heterogeneity, and hyperfibrinolysis; evaluating the Netherlands’ switch to solvent/detergent plasma". His studies focussed on the changing use of plasma transfusions at national level in The Netherlands, and internationally, including an analysis of information from the ISTARE database of the International Haemovigilance Network. He was supervised by Prof. J.G. (Anske) van der Bom and Dr Martin Schipperus.

Nic was an academic visitor to Monash during 2017, working on a range of transfusion research projects. Prof Erica Wood from the TRU was a member of the PhD defence panel for the University of Leiden.

The Asia-Pacific Myeloma and Related Diseases Registry has opened to recruitment at Samsung Medical Center in Korea!

The APAC MRDR is a clinical registry which collects health information on patients diagnosed with multiple myeloma, or related diseases such as plasmacytoma, plasma cell leukaemia, or monoclonal gammopathy of undetermined significance (MGUS) living in the Asia-Pacific region.

The registry was established in 2018 by Monash University, and in collaboration with participating pilot hospitals in Korea, Singapore, Hong Kong and Taiwan, and is affiliated with the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).

The APAC MRDR aims to provide health care services and researchers an important resource for investigating the best possible treatment options for people with these conditions. The Registry will tell us about:

  • the usefulness and results of available treatments over time
  • the variation in care provided and how this compares to best practice internationally

The Registry will also form a network of clinical experts from the Asia-Pacific region with a special interest in myeloma and related diseases.

Information on the Asia-Pacific expansion of the MRDR is available at: apacmrdr.org or please contact the project team at sphpm.apacmrdr@monash.edu

More information on the Australian and New Zealand MRDR and its projects is available at: mrdr.net.au

TRU awarded $1.75m for DIAAMOND PROJECT

Erica Wood and Zoe McQuilten of Monash University’s Transfusion Research Unit, in collaboration with colleagues from across Australia, have been awarded $1.75 million funding from the Medical Research Future Fund for the DIAAMOND project: Diagnosis of aplastic anaemia, management, and outcomes utilising a national dataset.

Aplastic anaemia is a life-threatening condition, and the only curative option, haematopoietic stem cell transplant, is not available to many patients. This study of avatrombopag (a second-generation thrombopoietin receptor agonist) in patients with treatment-naïve or relapsed/refractory aplastic anaemia, builds on promising results from recent studies with eltrombopag. The trial, using a novel Bayesian adaptive design, will be conducted using the Aplastic Anaemia Registry and is anticipated to open in early 2019.

If you are interested in participating in the Aplastic Anaemia Registry, or the DIAAMOND study, please contact us at: aar@monash.edu or sphpm.diaamond@monash.edu